시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 발기부전 치료제 시장 보고서(2025년)
Drugs For Erectile Dysfunction Global Market Report 2025
상품코드 : 1815652
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,430,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,294,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,159,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

발기부전 치료제 시장 규모는 향후 수년간 약간의 성장이 예상됩니다. 2029년에 CAGR은 1.6%를 나타낼 것으로 예측되고 44억 2,000만 달러로 성장할 전망입니다. 예측 기간 동안의 성장은 정신 건강 통합에 주력하는 점, 소비자 선호도 변화, 신흥 경제국 시장 확대, 재생 의학 연구, 바이오의약품 혁신 등에 기인할 수 있습니다. 예측 기간의 주요 동향에는 신약 개발, 인식 제고 및 교육 확대, 생활 방식 변화와 건강 의식 향상, 원격의료 및 온라인 상담, 혁신적인 투여 시스템 등이 포함됩니다.

향후 5년간 1.6% 성장이라는 전망은 해당 시장에 대한 이전 예측과 동일하게 유지됩니다. 이 감소는 주로 미국과 다른 국가 간 관세의 영향 때문입니다. 관세 부과로 푸에르토리코와 영국에서 원하는 포스포디에스테라제 5형 억제제(PDE5 억제제) 비용이 증가하여 성 건강 클리닉에 상당한 도전 과제가 될 수 있으며, 이는 치료 접근성을 감축하고 남성 웰빙 비용 증가로 이어질 수 있습니다. 또한 상호 관세 부과와 무역 긴장 및 제한 강화로 인한 전 세계 경제 및 무역에 대한 부정적 영향으로 그 영향이 더욱 광범위하게 될 것입니다.

만성 질환의 상당한 증가는 발기부전 의약품 시장의 주요 촉진 요인입니다. 발기부전은 주로 심혈관 질환, 당뇨병, 비만, 고혈압 등 좌식 생활 방식으로 인한 만성 질환과 연관되어 있습니다. 세계보건기구(WHO)가 2023년 9월 보고한 바에 따르면, 만성 질환은 연간 4,100만 명의 사망 원인으로 전 세계 사망자의 74%를 기록합니다. 만성 질환의 유병률은 남성의 발기부전 발생 가능성을 높여 결과적으로 발기부전 의약품 시장을 촉진합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별, 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

Erectile dysfunction (ED) drugs are medications utilized to enhance the effects of nitric oxide, a naturally occurring substance in the body that relaxes penile muscles, aiming to address erectile dysfunction, which is the inability to achieve or maintain a penile erection in men.

Various types of ED drugs include sildenafil citrate, mirodenafil, and vardenafil. Sildenafil, available under trade names such as Viagra, is used to treat erectile dysfunction and pulmonary arterial hypertension. Its effectiveness in treating female genital dysfunction remains uncertain. These drugs can be administered orally, topically, or via injections, and are commonly distributed through hospital pharmacies, retail pharmacies, and online platforms.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The drugs for erectile dysfunction market research report is one of a series of new reports from The Business Research Company that provides drugs for erectile dysfunction market statistics, including drugs for erectile dysfunction industry global market size, regional shares, competitors with drugs for erectile dysfunction market share, detailed drugs for erectile dysfunction market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for erectile dysfunction industry. This drugs for erectile dysfunction market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drugs for erectile dysfunction market size has declined marginally in recent years. It will grow from $4.16 billion in 2024 to $4.15 billion in 2025 at a compound annual growth rate (CAGR) of -0.2%. The growth in the historic period can be attributed to introduction of pde5 inhibitors, pharmaceutical marketing and advertising, changing societal attitudes, rise in lifestyle-induced ed cases, generic medication availability.

The drugs for erectile dysfunction market size is expected to see marginal growth in the next few years. It will grow to $4.42 billion in 2029 at a compound annual growth rate (CAGR) of 1.6%. The growth in the forecast period can be attributed to focus on mental health integration, shift in consumer preferences, market expansion in emerging economies, regenerative medicine exploration, biopharmaceutical innovations. Major trends in the forecast period include development of novel therapies, increasing awareness and education, lifestyle changes and health awareness, telemedicine and online consultations, innovative delivery systems.

The forecast of 1.6% growth over the next five years remains unchanged from the previous projection for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for sexual health clinics by increasing costs of phosphodiesterase type 5 inhibitors sourced from Puerto Rico and the UK, potentially reducing treatment accessibility and raising men's wellness expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The significant rise in the number of chronic diseases is a key driver for the erectile dysfunction drug market. Erectile dysfunction is primarily linked to chronic conditions resulting from a sedentary lifestyle, such as cardiovascular diseases, diabetes, obesity, and high blood pressure. As reported by the World Health Organization (WHO) in September 2023, chronic diseases are responsible for 41 million deaths annually, accounting for 74% of all global deaths. The prevalence of chronic diseases heightens the likelihood of erectile dysfunction among men, consequently propelling the market for erectile dysfunction drugs.

The increasing prevalence of hypertension is anticipated to fuel the growth of the drugs for erectile dysfunction market in the foreseeable future. Hypertension, characterized by sustained high blood pressure against the artery walls, is a prevalent medical condition. Erectile dysfunction drugs, such as sildenafil, contribute to managing hypertension by improving blood vessel function, lowering blood pressure, and promoting overall cardiovascular health through enhanced blood flow. For instance, the World Health Organization (WHO) reported in March 2023 that an estimated 1.28 billion adults aged 30-79 years worldwide have hypertension, with two-thirds residing in low- and middle-income countries. Hence, the escalating prevalence of hypertension is a driving factor in the growth of the drugs for erectile dysfunction market.

Several companies in the erectile dysfunction drugs market are implementing new drug delivery techniques, such as pellets and creams. These innovations offer increased efficacy, performance, and safety in treating erectile dysfunction. For example, in September 2022, Lupin, an India-based pharmaceutical company, launched Sildenafil for oral suspension, 10 mg/mL, approved by the United States Food and Drug Administration (FDA). This drug delivery method provides unique dosages for treating erectile dysfunction, enhancing treatment options and potentially addressing concerns related to side effects.

Major players in the drugs for erectile dysfunction market are strategically focusing on introducing combination capsules, such as therapy capsules, to optimize revenue. Tamsulosin and Tadalafil, a combination of medications targeting benign prostatic hyperplasia (BPH) and erectile dysfunction, is gaining prominence. In September 2023, Akums Drugs & Pharmaceuticals Ltd., an India-based pharmaceutical company, launched a therapy capsule addressing both conditions in the Indian market. This capsule, containing a combination of Tamsulosin and Tadalafil, demonstrates significant improvements in BPH and the Erectile Dysfunction Index. The introduction of such therapy capsules provides a novel treatment option for patients grappling with both conditions, catering to a broader spectrum of needs in the market.

Major companies operating in the drugs for erectile dysfunction market include Pfizer Inc., Eli Lilly and Company, Bayer AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Futura Medical plc, Zydus Cadila, Lupin Limited, Cipla Limited, Dong-A Pharmaceutical Co., Ltd., Aurobindo Pharma Ltd., Alembic Pharmaceuticals Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., AvKARE Inc., Endo Pharmaceuticals Inc., Teva Pharmaceutical USA, Aurobindo Pharma USA, Hims & Hers Health Inc., Antares Pharma Inc., Acrux Limited, Mankind Pharma Ltd., Futura Medical plc, Adamis Pharmaceuticals Corporation

North America was the largest region in the drugs for erectile dysfunction market in 2024. Middle East is expected to be the fastest-growing region in the global drugs for erectile dysfunction market during the forecast period. The regions covered in the drugs for erectile dysfunction market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the drugs for erectile dysfunction market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The erectile dysfunction (ED) drugs market consists of sales Sildenafil (Viagra), vardenafil (Levitra, Staxyn), tadalafil (Cialis) and avanafil (Stendra). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Drugs For Erectile Dysfunction Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on drugs for erectile dysfunction market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for drugs for erectile dysfunction ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drugs for erectile dysfunction market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Drugs For Erectile Dysfunction Market Characteristics

3. Drugs For Erectile Dysfunction Market Trends And Strategies

4. Drugs For Erectile Dysfunction Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Drugs For Erectile Dysfunction Growth Analysis And Strategic Analysis Framework

6. Drugs For Erectile Dysfunction Market Segmentation

7. Drugs For Erectile Dysfunction Market Regional And Country Analysis

8. Asia-Pacific Drugs For Erectile Dysfunction Market

9. China Drugs For Erectile Dysfunction Market

10. India Drugs For Erectile Dysfunction Market

11. Japan Drugs For Erectile Dysfunction Market

12. Australia Drugs For Erectile Dysfunction Market

13. Indonesia Drugs For Erectile Dysfunction Market

14. South Korea Drugs For Erectile Dysfunction Market

15. Western Europe Drugs For Erectile Dysfunction Market

16. UK Drugs For Erectile Dysfunction Market

17. Germany Drugs For Erectile Dysfunction Market

18. France Drugs For Erectile Dysfunction Market

19. Italy Drugs For Erectile Dysfunction Market

20. Spain Drugs For Erectile Dysfunction Market

21. Eastern Europe Drugs For Erectile Dysfunction Market

22. Russia Drugs For Erectile Dysfunction Market

23. North America Drugs For Erectile Dysfunction Market

24. USA Drugs For Erectile Dysfunction Market

25. Canada Drugs For Erectile Dysfunction Market

26. South America Drugs For Erectile Dysfunction Market

27. Brazil Drugs For Erectile Dysfunction Market

28. Middle East Drugs For Erectile Dysfunction Market

29. Africa Drugs For Erectile Dysfunction Market

30. Drugs For Erectile Dysfunction Market Competitive Landscape And Company Profiles

31. Drugs For Erectile Dysfunction Market Other Major And Innovative Companies

32. Global Drugs For Erectile Dysfunction Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Drugs For Erectile Dysfunction Market

34. Recent Developments In The Drugs For Erectile Dysfunction Market

35. Drugs For Erectile Dysfunction Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기